UnitedHealth Group (NYSE: UNH) has faced a tough year, dropping 40% year-to-date and 42.2% in the last three months. However, recent leadership changes and insider investments suggest a potential recovery. Former CEO Andrew Witty resigned, replaced by Stephen J. Hemsley, who aims to return to 13-16% long-term growth.

Insiders and Congressional representatives are buying UNH shares, with Hemsley purchasing $25 million worth of stock. UnitedHealth executives express optimism for growth in 2026, despite past challenges. Hemsley plans to rebuild trust, review underperforming areas, and establish a 2025 earnings outlook. Pricing disciplines and financial oversight are key focuses for the company.

Analysts predict a 35.61% upside for UNH stock, with a consensus Moderate Buy rating. UBS analyst AJ Rice supports UnitedHealth, believing the new management team’s approach will provide stability. The average price target is $415.57, indicating potential growth. Analysts anticipate a conservative 2025 outlook that aligns with the company’s deliverability.

Read more at Nasdaq: Do They Know Something? Insiders & Congress Buy UnitedHealth